Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Edscharp who wrote (16170)	1/9/2003 3:09:15 PM
From: Bluegreen	Respond to of 17367

Ed, the LAST time you waited on the musical Xoma went to around 17 per share. I wonder where the price will go IF Raptiva gets approval? In my opinion IF Amevive gets approved everyone will then QUICKLY turn their attention to Biogen's sales THEN everyone will start worrying about how Raptiva if approved will affect Biogen's numbers THEN BIG FOCUS might just be on........RAPTIVA.......it seems to ALWAYS happen this way in Biotech. BTW, what do you think the price of Xoma will be IF Raptiva approved for psoriasis AND if positive results on the Raptiva rheumatoid arthritis trial????